东曜药业-B(01875)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01875 东曜药业-B

休市中 12-05 13:18:05

1.710

-0.010

-0.58%

最高1.740	最低1.700	成交量10.80万
今开1.720	昨收1.720	日振幅2.33%
总市值13.22亿	流通市值13.21亿	总股本7.73亿
成交额18.46万	换手率0.01%	流通股本7.73亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01875","market":"HK","secType":"STK","nameCN":"东曜药业-B","latestPrice":1.71,"timestamp":1764911885124,"preClose":1.72,"halted":0,"volume":108000,"delay":0,"floatShares":772787887,"shares":773000000,"eps":0.05278525529181878,"marketStatus":"休市中","change":-0.01,"latestTime":"12-05 13:18:05","open":1.72,"high":1.74,"low":1.7,"amount":184628,"amplitude":0.023256,"askPrice":1.75,"askSize":800,"bidPrice":1.71,"bidSize":7200,"shortable":0,"etf":0,"ttmEps":0.011025793200625909,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":7,"adr":0,"listingDate":1573142400000,"exchange":"SEHK","adjPreClose":1.72,"openAndCloseTimeList":[[1764898200000,1764907200000],[1764910800000,1764921600000]],"volumeRatio":1.6728624504221887,"lotSize":400,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01875","defaultTab":"news","newsList":[{"id":"1140957185","title":"东曜药业（1875）11月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1140957185","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140957185?lang=zh_cn&edition=full","pubTime":"2025-12-04 17:16","pubTimestamp":1764839781,"startTime":"0","endTime":"0","summary":"东曜药业股份有限公司（01875）于2025年12月4日发布11月股份变动月报，报告期为2025年11月1日至11月30日。公司披露，截至本月末，已发行股份总数为772,787,887股，与上月持平，未有新增发行、购回或注销股份行为。\n公司同时披露有关股份期权计划情况：期末总计7,759,600股期权维持不变，本月内未有授出、行使或失效事宜。截至2025年11月30日，公司股本及发行在外股份数保持稳定。\n公告显示，公司确认已遵守香港联合交易所有限公司《上市规则》和相关法律规定。月报由联席公司秘书吕颖一签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01875"],"gpt_icon":0},{"id":"2586382294","title":"东曜药业-B11月26日主力净流入53.4万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2586382294","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586382294?lang=zh_cn&edition=full","pubTime":"2025-11-26 16:15","pubTimestamp":1764144906,"startTime":"0","endTime":"0","summary":"11月26日，东曜药业-B股价收平报1.78元，成交金额63.0万元，换手率0.05%，振幅3.37%，量比9.08。东曜药业-B今日主力资金净流入53.4万元，上一交易日主力净流出0万元。该股近5个交易日下跌4.30%，主力资金累计净流入53.4万元；近20日主力资金累计净流入53.4万元，其中净流入天数为1日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126161522a4bb5364&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126161522a4bb5364&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","01875"],"gpt_icon":0},{"id":"2585113379","title":"2025年国产药物出海大爆发，获批上市捷报频传","url":"https://stock-news.laohu8.com/highlight/detail?id=2585113379","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585113379?lang=zh_cn&edition=full","pubTime":"2025-11-21 15:41","pubTimestamp":1763710901,"startTime":"0","endTime":"0","summary":"2025年国产药物出海以 License - out 为代表的 BD 交易就已迎来跨越式增长。资料显示，截至10月份，2025年中国创新药BD交易总额已超过千亿美元。值得一提的是，截至目前，复宏汉霖已有7款产品于海外获批上市，其中4款产品在美国获批上市。10月下旬，东曜药业宣布贝伐珠单抗生物类似药正式获得玻利维亚国家药品与卫生技术局批准上市，此次获批是贝伐珠单抗在海外上市的第五个国家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251121154551a4b10ab6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251121154551a4b10ab6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01875","HK0000165453.HKD","02696","BK1161"],"gpt_icon":0},{"id":"2583316485","title":"东曜药业：前三季度营收为6.22亿元，自研产品市场竞争愈加激烈","url":"https://stock-news.laohu8.com/highlight/detail?id=2583316485","media":"财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583316485?lang=zh_cn&edition=full","pubTime":"2025-11-12 18:32","pubTimestamp":1762943559,"startTime":"0","endTime":"0","summary":"近日，东曜药业发布公告称，截至2025年9月30日止九个月，公司营业收入为6.22亿元，较去年同期下降23%，主要原因是自研产品的市场竞争愈加激烈。净利润方面，公司在此期间出现亏损，净亏损为337万元，而去年同期则实现净利润3540万元。在资产负债表方面，截至2025年9月30日，公司流动资产为6.56亿元，非流动资产为7.21亿元，流动负债为2.66亿元，非流动负债为3.85亿元，净资产总额为7.26亿元，较2024年12月31日的7.3亿元略有下降。此次财务数据为未经过审计，可能会在进一步内部审阅后进行调整。（东曜药业公告）(编辑：杨燕 林辰)关键字： 医疗","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111218353694ffb348&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111218353694ffb348&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","01875"],"gpt_icon":0},{"id":"2582935057","title":"东曜药业-B(01875)前三季度营业收入6.22亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2582935057","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582935057?lang=zh_cn&edition=full","pubTime":"2025-11-11 18:10","pubTimestamp":1762855852,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东曜药业-B(01875)发布公告，截至2025年9月30日止九个月期间，集团的营业收入为人民币6.22亿元；期内及公司权益持有人应占净亏损337.1万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01875"],"gpt_icon":0},{"id":"2576003678","title":"东曜药业高管变动，CEO兼CSO辞职！","url":"https://stock-news.laohu8.com/highlight/detail?id=2576003678","media":"药融圈","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576003678?lang=zh_cn&edition=full","pubTime":"2025-10-19 10:32","pubTimestamp":1760841144,"startTime":"0","endTime":"0","summary":"10月13日晚，东曜药业发布公告，付山先生自2025年10月11日起由公司非执行董事调任为执行董事，并负责领导并监督本集团的管理与发展，并继续担任公司董事长。黄纯莹女士，于2010年7月5日加入东曜药业股份有限公司，并于2016年1月19日获委任为东曜药业股份有限公司执行董事。彼现时担任东曜药业股份有限公司执行董事兼总经理。于2020年10月15日委任为东曜药业股份有限公司董事会副主席。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251019110830a4674f8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251019110830a4674f8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","01875"],"gpt_icon":0},{"id":"2575974125","title":"东曜药业：CEO刘博士与副董事长黄女士因家庭原因辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=2575974125","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575974125?lang=zh_cn&edition=full","pubTime":"2025-10-16 17:33","pubTimestamp":1760607212,"startTime":"0","endTime":"0","summary":"10月16日，东曜药业（01875）发布公告，因个人原因，刘博士辞任公司执行董事、首席执行官、首席科学官及战略与ESG委员会成员，黄女士辞任公司非执行董事、副董事长及战略与ESG委员会成员。公告补充说明，刘博士及黄女士均因家庭原因辞任上述职务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251016173420a46304c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251016173420a46304c5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01875","BK1161","BK1574"],"gpt_icon":0},{"id":"2575741283","title":"这家医药CDMO企业CEO离职！ ADC赛道的战略抉择","url":"https://stock-news.laohu8.com/highlight/detail?id=2575741283","media":"中国制药网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575741283?lang=zh_cn&edition=full","pubTime":"2025-10-16 10:02","pubTimestamp":1760580149,"startTime":"0","endTime":"0","summary":"CDMO/CMO业务收入人民币207,133千元，同比增长47%。得益于公司高效的研发平台，报告期内东曜药业协助客户完成获批临床的双载荷ADC项目。东曜药业表示，主要原因为部分关键项目尚未达到交付节点。对于聚焦 ADC 赛道的东曜而言，管理层更迭恰逢行业竞争关键期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101610104394cc03c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101610104394cc03c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01875","09939","BK1574","BK1515","BK1161"],"gpt_icon":0},{"id":"2575414027","title":"年薪超五百万！这一药企CEO辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=2575414027","media":"医药代表","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575414027?lang=zh_cn&edition=full","pubTime":"2025-10-16 07:12","pubTimestamp":1760569927,"startTime":"0","endTime":"0","summary":"10 月 13 日，东曜药业股份有限公司发布公告，宣布了多个高管人事变动。除此之外，自 2025 年 10 月 11 日起，付山由东曜药业非执行董事调任为执行董事，并负责领导并监督东曜药业的管理与发展。据公告，刘军、黄纯莹两人辞任后将获聘为东曜药业策略顾问。2020 年 10 月 15 日，刘军被任命为东曜药业首席执行官。据公开信息，刘军 2023 年在东曜药业薪酬总额为 752.8 万元，2023 年薪酬总额为 566.3 万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101607203294cbb5cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101607203294cbb5cb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","01875"],"gpt_icon":0},{"id":"2575747683","title":"东曜药业-B(01875)：付山由非执行董事调任为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2575747683","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575747683?lang=zh_cn&edition=full","pubTime":"2025-10-13 16:46","pubTimestamp":1760345218,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东曜药业-B 发布公告，付山先生自2025年10月11日起由公司非执行董事调任为执行董事，并负责领导并监督集团的管理与发展。继刘博士离任董事后，付先生已根据上市规则第3.05条的规定获委任为公司授权代表以接替刘博士，该委任自2025年10月11日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1354255.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01875","BK1574","BK1161"],"gpt_icon":0},{"id":"2569928788","title":"ADC CDMO业绩及订单盘点：药明合联、东曜药业、皓元医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2569928788","media":"生物药大时代","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569928788?lang=zh_cn&edition=full","pubTime":"2025-09-22 11:36","pubTimestamp":1758512188,"startTime":"0","endTime":"0","summary":"2025年上半年，药明合联、东曜药业、皓元医药这三家深耕ADC领域的CDMO企业，已陆续交出中期答卷。作为龙头药明系的一分子，药明合联自然也是ADCCDMO的龙头，其2025年上半年营收达27亿，净利润也高达7.46亿元。东曜药业营收同比下降6.04%，净利润同比大幅下滑72.40%，是三者中唯一出现负增长的企业，主要原因系部分项目未支付和折旧摊销增加所致。已签约未完成订单达人民币2亿元。同时东曜药业协助客户完成全球首个获批临床的双载荷ADC项目。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922130651a43b8d63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922130651a43b8d63&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02268","01875","SG9999014674.SGD","LU2488822045.USD","BK1141"],"gpt_icon":0},{"id":"2562729736","title":"东曜药业-B大跌5.31% 上半年净利润同比暴跌87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562729736","media":"港美通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562729736?lang=zh_cn&edition=full","pubTime":"2025-08-26 14:00","pubTimestamp":1756188051,"startTime":"0","endTime":"0","summary":"8月26日13:54，东曜药业-B大跌5.31%，该股报2.140港元，最高报2.230港元，最低报2.150港元，成交量29.64万股，成交额65.07万港元。消息面上，东曜药业-B近日发布截至2025年6月30日的中期业绩公告，公司营业收入为4.89亿元，同比下降6%。其中，产品销售收入为3.98亿元，同比下降1%，主要原因是市场竞争加剧。CDMO/CMO业务收入为7730万元，同比下降32%，主要是由于部分关键项目尚未达到交付节点。公司上半年净利润为406万元，同比下降87%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082614101194fd41c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082614101194fd41c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01875"],"gpt_icon":0},{"id":"1197111064","title":"异动解读 | 东曜药业-B盘中大跌7.63%，中期业绩净利润大幅下滑87%","url":"https://stock-news.laohu8.com/highlight/detail?id=1197111064","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197111064?lang=zh_cn&edition=full","pubTime":"2025-08-13 09:32","pubTimestamp":1755048763,"startTime":"0","endTime":"0","summary":"今日盘中，东曜药业-B股价大幅下跌7.63%，引发市场关注。这一显著跌幅很可能与公司最新发布的2025年中期业绩报告有关。根据东曜药业-B于昨日晚间发布的2025年中期财报，公司收益为4.89亿元人民币，同比下降6%。更值得注意的是，公司净利润仅为406.2万元人民币，同比大幅下滑87.13%。每股盈利降至0.01元人民币，公司决定不派发中期股息。市场对东曜药业-B短期盈利能力的担忧可能是导致股价大跌的主要原因。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01875"],"gpt_icon":0},{"id":"2558408076","title":"东曜药业-B(01875)上半年CDMO技术领跑行业 核心产品全球化布局实现突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2558408076","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558408076?lang=zh_cn&edition=full","pubTime":"2025-08-12 21:51","pubTimestamp":1755006691,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东曜药业-B 公布2025年中期业绩，营收约4.89亿元，净利润约406.2万元。得益于公司高效的研发平台，报告期内东曜药业协助客户完成全球首个获批临床的双载荷ADC项目。2025年上半年，该产品已成功通过尼日利亚及巴基斯坦药品监管局的上市批准。后续，东曜药业将负责贝伐珠单抗注射液全球的商业化生产。尼日利亚、巴基斯坦的上市获批开启了东曜药业的国际化商业供应，是公司以国际化质量体系及商业化能力开拓全球市场的又一大突破。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1328769.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK1161","01875","BK1574","CDMO"],"gpt_icon":0},{"id":"2557330948","title":"百济神州要切入“CXO”，赛道未来是生态局？","url":"https://stock-news.laohu8.com/highlight/detail?id=2557330948","media":"盖德化工网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557330948?lang=zh_cn&edition=full","pubTime":"2025-08-05 08:00","pubTimestamp":1754352034,"startTime":"0","endTime":"0","summary":"百济神州“组局”，想切入CXO？据分析，百济神州在美国已拥有完整的临床和商业化团队，邀请国内新药组局“NewCo出海”，很有可能想切入“CXO”领域：一是百济神州全球组建有超3700人的临床团队，需要大量的资金用以维持这支庞大团队的高速运转。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805081046a4754452&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805081046a4754452&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0588546209.SGD","01875","LU2328871848.SGD","688235","WXIBF","BK1500","06160","BK1583","BK1588","LU1969619763.USD","02142","BK1161","ONC","02269","LU0307460666.USD"],"gpt_icon":0},{"id":"2555070880","title":"东曜药业-B拟8月12日举行董事会会议批准中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2555070880","media":"格隆汇","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555070880?lang=zh_cn&edition=full","pubTime":"2025-07-31 16:35","pubTimestamp":1753950900,"startTime":"0","endTime":"0","summary":"格隆汇7月31日丨东曜药业-B(01875.HK)宣布，公司谨定于2025年8月12日（星期二）举行董事会会议，以考虑及通过集团截至2025年6月30日止六个月中期业绩，以及处理其他事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507311637499729a943&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507311637499729a943&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01875","BK1161","BK1574"],"gpt_icon":0},{"id":"2554167769","title":"东曜药业-B(01875)：英文股份简称将更改为“BIODLINK-B”","url":"https://stock-news.laohu8.com/highlight/detail?id=2554167769","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554167769?lang=zh_cn&edition=full","pubTime":"2025-07-25 18:49","pubTimestamp":1753440587,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东曜药业-B(01875)公布，公司用作于联交所买卖股份的英文股份简称将由“TOT BIOPHARM-B”更改为“BIODLINK-B”，自2025年7月30日上午九时正起生效。公司中文股份简称“东曜药业-B”及股份代号“1875”维持不变。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322088.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","01875"],"gpt_icon":0},{"id":"2552212231","title":"东曜药业-B07月16日主力净流入4.6万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2552212231","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552212231?lang=zh_cn&edition=full","pubTime":"2025-07-16 16:15","pubTimestamp":1752653738,"startTime":"0","endTime":"0","summary":"07月16日，东曜药业-B股价收平报1.90元，成交金额73.0万元，换手率0.05%，振幅1.05%，量比3.40。东曜药业-B今日主力资金净流入4.6万元，上一交易日主力净流出0万元。该股近5个交易日上涨3.26%，主力资金累计净流入4.6万元；近20日主力资金累计净流入4.6万元，其中净流入天数为1日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716170332a6ad11ad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716170332a6ad11ad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01875","BK1161","BK1574"],"gpt_icon":0},{"id":"2547600560","title":"2025东曜药业私董会：让中国方案，成为全球答案！","url":"https://stock-news.laohu8.com/highlight/detail?id=2547600560","media":"药时代","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547600560?lang=zh_cn&edition=full","pubTime":"2025-06-30 17:41","pubTimestamp":1751276495,"startTime":"0","endTime":"0","summary":"近日，由东曜药业携手BioPlus、科百特、纳微科技、恒驭生物共同呈现的“创药潮头，并肩出海”私董会在苏州成功举办。未来，东曜药业将以BioDlink为新起点，将持续开放国际化能力池，与行业共拓“创药潮头，并肩出海”的新航海时代——让中国方案，成为全球答案。在质量体系方面，东曜药业质量管","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630174835a4c652b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630174835a4c652b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01875","BK1574","BK1161"],"gpt_icon":0},{"id":"1180591335","title":"港股生物医药B类股表现强势，云顶新耀-B涨近13%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180591335","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180591335?lang=zh_cn&edition=full","pubTime":"2025-03-07 10:45","pubTimestamp":1741315530,"startTime":"0","endTime":"0","summary":"港股异动｜生物医药B类股表现强势，$云顶新耀-B(01952)$涨近13%，$心通医疗-B(02160)$涨近10%，$腾盛博药-B(02137)$涨近8%，$东曜药业-B(01875)$涨6%","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"770b5ee9faa86b3f893c8112c563956a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSTECH","01875","02160","YANG","HSCEI","BK1161","07226","02137","BK1583","01952","BK1574","BK1587","BK1100"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.totbiopharm.com.cn","stockEarnings":[{"period":"1week","weight":-0.0393},{"period":"1month","weight":-0.132},{"period":"3month","weight":-0.2934},{"period":"6month","weight":-0.1276},{"period":"1year","weight":-0.05},{"period":"ytd","weight":-0.0447}],"compareEarnings":[{"period":"1week","weight":0.0087},{"period":"1month","weight":0.0058},{"period":"3month","weight":0.0262},{"period":"6month","weight":0.0964},{"period":"1year","weight":0.3336},{"period":"ytd","weight":0.3004}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"东曜药业股份有限公司是一家临床阶段生物制药公司，主要从事开发及商业化肿瘤药物及疗法。该公司的主营业务在中华人民共和国从事抗肿瘤药物的研究与开发、生产及营销、合约开发生产组织（CDMO）/合约生产组织（CMOJ）业务以及自主开发生物药物的对外许可。该公司拥有针对各类癌症的在研肿瘤药物管线，当中包括单克隆抗（mAb）及抗体偶联药物（ADC）。该公司已建立起一个集发现、产程开发、质量管理临床前及临床开发以及商业规模的生产基地和销售及营销能力于一体的综合内部平台。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.065981},{"month":2,"riseRate":0,"avgChangeRate":-0.043389},{"month":3,"riseRate":0.5,"avgChangeRate":-0.024422},{"month":4,"riseRate":0.833333,"avgChangeRate":0.069994},{"month":5,"riseRate":0.666667,"avgChangeRate":0.07905},{"month":6,"riseRate":0.666667,"avgChangeRate":-0.001367},{"month":7,"riseRate":0.333333,"avgChangeRate":0.023634},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.052288},{"month":9,"riseRate":0.666667,"avgChangeRate":0.011349},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.041625},{"month":11,"riseRate":0,"avgChangeRate":-0.064081},{"month":12,"riseRate":0.571429,"avgChangeRate":-0.021325}],"exchange":"SEHK","name":"东曜药业-B","nameEN":"BIODLINK-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东曜药业-B(01875)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东曜药业-B(01875)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东曜药业-B,01875,东曜药业-B股票,东曜药业-B股票老虎,东曜药业-B股票老虎国际,东曜药业-B行情,东曜药业-B股票行情,东曜药业-B股价,东曜药业-B股市,东曜药业-B股票价格,东曜药业-B股票交易,东曜药业-B股票购买,东曜药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东曜药业-B(01875)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东曜药业-B(01875)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}